




All-Natural Option for Canine Joint Lameness

WHAT IS PRO-STRIDE?

Pro-Stride APS is an innovative device in which the output produces a *concentrated* solution of cells, platelets, growth factors, and anti-inflammatory proteins.¹

Using the patient's own blood, the Pro-Stride APS device separates and concentrates (in under 20 minutes of processing), allowing for administering of the output in a single visit.²



PRACTICE BENEFITS

- All-natural option for pet owners.
- Clinically demonstrated effectiveness.²⁻⁶
- Unique service offering to differentiate from other practices.
- New revenue stream.



OWL MANOR VETERINARY®

THE PRO-STRIDE DIFFERENCE






The Pro-Stride APS device processes the dog's own blood at the point-of-care by first isolating platelets and white blood cells in a small volume of plasma then further concentrating these components with desiccating beads.⁷

Platelet-rich plasma (PRP) device processes blood to produce an output with an increased concentration of platelets compared to baseline blood.⁸

The output of the Pro-Stride APS device contains greater concentrations of white blood cells, anti-inflammatory cytokines, and anabolic growth factors than the output of PRP devices.⁸⁻⁹

Addressing Inflammatory Imbalance



Pro-Stride APS's output is neither PRP nor an autologous conditioned serum (ACS).

LEARN MORE

888.925.8269
www.omveterinary.com/pro-stride
info@owlmanormedical.com

References

- O'Shaughnessy et al. Autologous protein solution prepared from the blood of osteoarthritic patients contains an enhanced profile of anti-inflammatory cytokines and anabolic growth factors. JOR 2014, 32, 1349-1355.
- Wanstrath et al., Evaluation of a single intra-articular injection of autologous protein solution for treatment of osteoarthritis in a canine population. Veterinary Surgery 2016, 45 (6):764-774.
- Bertone et al., Evaluation of a single intra-articular injection of autologous protein solution for treatment of osteoarthritis in horses. AJVR 2014, 75 (2), 141-151.
- O'Shaughnessy et al., Blood-derived anti-inflammatory protein solution blocks the effect of IL-1 β on human macrophages in vitro. Inflammation Research 2011, 60 (10), 929-936.
- Woodell-May et al., Autologous protein solution inhibits MMP-13 production by IL-1 β and TNF α -stimulated human articular chondrocytes. JOR 2011, 29 (9), 1320-1326.
- King, W. et al., Human blood-based anti-inflammatory solution inhibits osteoarthritis progression in a meniscal-tear rat study. JOR 2017, 35 (10), 2260-2268.
- King, W.; Woodell-May, J., Comparison of the cellular and cytokine concentrations in the output of the autologous protein solution, orthokine, and onocommed 2 device systems. Osteoarthritis and Cartilage 2014, 22, S484.
- King, W.; Toler, K.; Woodell-May, J., Role of white blood cells in blood-and bone marrow-based autologous therapies. BioMed Research International 2018.
- King, W.; Steckbeck, K.; O'Shaughnessy, K.; Woodell-May, J., Effect of preparation technique on anti-inflammatory properties of autologous therapies. Orthopedic Research Society Annual meeting 2015.